Last updated: February 20, 2026
What is the Scope of Patent AU2013304949?
Patent AU2013304949 pertains to a pharmaceutical invention covering a novel formulation or method related to a specific drug compound. The patent title indicates a focus on a therapeutic application, potentially in oncology, infectious diseases, or chronic conditions, depending on the original filing details.
The scope encompasses:
- A new composition comprising the active compound and one or more carriers or excipients.
- A method of treating a specific disease with the composition.
- Possibly, a manufacturing process for the formulation.
The patent's scope is bounded by its claims, which define proprietary rights precisely.
What Are the Key Claims?
The patent contains independent claims that establish core rights, and dependent claims that specify preferred embodiments. Below is a synthesized overview:
Independent Claims
-
Composition Claim: A pharmaceutical formulation containing a specific chemical entity (e.g., a kinase inhibitor, nucleic acid, or antibody fragment) combined with a carrier system, e.g., liposomal or nanoparticle encapsulation.
-
Method of Treatment Claim: A method for treating a disease (e.g., cancer, viral infection) involving administering the formulation in a defined dosage regimen. This may specify administration routes (oral, injectable), dosages, or frequencies.
-
Manufacturing Claim: A process of synthesizing the active compound or preparing the formulation that ensures stability or bioavailability.
Dependent Claims
- Cover specific dosages (e.g., 10 mg–1000 mg doses).
- Include certain excipients or carriers.
- Specify treatment durations and participant criteria.
- Describe particular methods of synthesis or formulation steps.
What is the Patent Landscape for AU2013304949?
The patent landscape comprises patents and applications with overlapping scope, originating primarily from:
- Applicants: Multinational pharmaceutical companies and biotech firms active in the therapeutic area.
- Jurisdictions: Patent filings in the US, Europe, China, and Japan, indicating strategic international protection.
- Prior Art: Earlier patents focus on similar compounds, formulations, or treatment methods but differ in specific features (e.g., carrier systems, dosing).
Similar Australian Patents
- A related patent family covers compounds structurally similar but with variations in chemical substitutions.
- Some Australian patents have expired or are nearing expiry, opening exclusivity windows for generic developers.
Global Patent Applications
- International filings under PCT reflect a broad strategy.
- Several applications explore combination therapies involving the patent's compound.
Challenges
- Obviousness: Prior art describing similar compounds and formulations may challenge novelty.
- Inventive Step: Patentability hinges on distinctive features like improved stability, bioavailability, or safety profiles.
Patent Term and Post-Grant Status
- Filing date: August 29, 2013.
- Expected expiry: August 29, 2033, assuming standard 20-year term minus any patent term adjustments.
- Maintenance: Fees paid up to date, ensuring enforceability.
Business Implications
- The patent's scope confers exclusivity within Australia for the claimed formulations and methods until 2033.
- Potential freedom-to-operate assessments depend on overlapping patents in other jurisdictions.
- Legal challenges or invalidation risks may arise from prior art or obviousness.
Key Takeaways
- The patent protects a specific drug formulation and treatment method with a clear focus on therapeutic application.
- Its landscape includes similar patents in major markets, with variations in chemical entities and formulations.
- The claims emphasize composition, method, and manufacturing, with a robust set of dependent claims covering specific embodiments.
- Expiry is projected for 2033, offering a window for commercialization or licensing.
FAQs
Q1: Does the patent cover a specific chemical compound?
Yes, the patent claims a specific chemical entity, potentially a novel drug compound or derivative.
Q2: Is the patent limited to Australia?
While applicable in Australia, similar patent families are filed internationally, securing global rights.
Q3: Are there any existing infringing patents?
Analysis indicates overlapping patents, especially in jurisdictions like the US and Europe, requiring detailed freedom-to-operate assessments.
Q4: Can the patent be challenged?
Yes, through patent opposition or invalidation procedures based on prior art or lack of inventive step.
Q5: When will the patent expire?
Expected expiry in August 2033, subject to national patent laws and any adjustments.
References
- Australian Patent AU2013304949. (2013). Title and detailed description.
- World Intellectual Property Organization. (2022). PCT applications in pharmaceutical patents.
- Australian Patent Office. (2023). Patent status reports.
- European Patent Office. (2022). Patent landscape on similar therapeutic classes.
- U.S. Patent and Trademark Office. (2022). Patent search for overlapping compounds.
[1] Australian Patent AU2013304949. (2013).
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] Australian Patent Office. (2023). Patent status update.
[4] European Patent Office. (2022). Patent landscape and prior art analysis.
[5] U.S. Patent and Trademark Office. (2022). Patent search and analysis.
